Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2025

Volume

146

Issue

1

First Page

667

Last Page

667

Published In/Presented At

https://doi.org/10.1182/blood-2025-667

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article